Key Highlights
- Net sales fell 4% to USD 206 million in the fiscal third quarter ended October 3, 2026, as USANA Health Sciences (NYSE:USNA) reported on November 3, 2026, from USD 214 million.
- The net loss narrowed to USD 5.6 million, or USD 0.30 per diluted share, from USD 6.5 million, or USD 0.36; adjusted diluted loss per share was USD 0.11 against USD 0.15.
- Fiscal 2026 adjusted EBITDA guidance moved to USD 77 million from a corrected USD 80.5 million, and consolidated net sales are now seen approaching USD 900 million.
- Core Nutritional active customers fell to 356,000 from 388,000, while Hiya active monthly subscribers rose 18% sequentially to 195,500.
Mixed Quarter Leads to a Lower Profit Outlook
USANA Health Sciences (NYSE:USNA) reported fiscal third quarter results for the period ended October 3, 2026 on November 3, 2026. Net sales were USD 206 million, down 4% from USD 214 million, and adjusted EBITDA attributable to the company was USD 12.1 million against USD 13.8 million. The net loss included income tax expense of USD 6 million on a pretax loss of about USD 1 million. The chief executive called the results mixed, with meaningful improvement in some areas and results that fell short of expectations in others. Guidance for fiscal 2026 now calls for a net loss of USD 16 million, adjusted Diluted Earnings per Share of USD 0.55 against USD 0.76 previously, and adjusted EBITDA of USD 77 million.
Hiya Spending Weighs on Margins as Core Customers Shrink
Management chose to raise Marketing spend at the Hiya subscription business, which pressured margins but lifted active monthly subscribers by about 29,500 sequentially and returned the segment to year-over-year sales growth of 2%, to USD 32 million. Customer Acquisition costs declined from the first half, and net sales through Target and Amazon more than doubled from the second quarter. Core Nutritional sales fell 3% to USD 171 million and active customers dropped 8%, with Greater China sales up 1% but active customers down 9%. Rise Wellness sales fell 45% to USD 4 million. The company said core Margin expanded on a leaner cost structure, and it is changing its Brand Partner incentive plan to reward growth in active customers.
A Corrected Baseline, Cash Position and What to Watch
The release corrects previously reported adjusted EBITDA attributable to USANA: the USD 29.1 million Hiya Goodwill Impairment had been added back in full rather than net of the USD 6.2 million attributable to the noncontrolling interest. The corrected second quarter figure is USD 21.7 million and the August 4, 2026 outlook becomes USD 80.5 million rather than about USD 87 million, a non-GAAP change with no effect on GAAP results. The company ended the quarter with USD 179 million of cash, no debt, USD 36 million of year-to-date free Cash Flow and about USD 34 million left on its buyback authorization, with no shares repurchased this quarter. Risks include continued customer attrition and Hiya margin pressure, while management expects sequential Hiya progress in the fourth quarter.
Where Things Stand
The outlook was cut because lower expectations at Rise Wellness and deliberate Hiya Investment outweighed stronger Core Nutritional profitability, according to the chief financial officer. USANA Health Sciences (NYSE:USNA) is also working from a corrected baseline, since the prior adjusted EBITDA guidance fell from about USD 87 million as first published to USD 80.5 million after the error was fixed. The Balance Sheet is solid, with USD 179 million of cash and no debt, but active customers in the core Business are still shrinking. Subscriber growth at Hiya and any early 2027 update on broader retail reach are the next items to watch.






Please wait processing your request...